As we look back at another busy year for the rare disease (RD) space, we also reflect on the continued growth of CRA’s rare disease capabilities and offerings. In the last five years, our consultants have undertaken over 700 client projects in rare diseases, constituting over 20% of our total client projects. In 2023, we completed over 130 projects on rare diseases, covering therapeutic categories from neurology to oncology and treatment modalities from cell and gene therapies to small molecules. We have also had the honor of presenting our insights at congresses, including World Orphan Drug Congress, BIO-Europe, and ISPOR. We have also published forward-looking thought leadership articles on rare disease issues.
It is a pleasure to present this review to showcase the breadth and depth of CRA’s activities, capabilities, and experience in rare diseases, and we look forward to our continued work with you on this expanding and exciting space in the years ahead.
